Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Rapid blood test offers new hope for people most at risk of TB

Tuberculosis (TB) is the leading cause of death from an infectious disease. Although a quarter of the world’s population is thought to carry latent TB, it carries a risk of progressing to the active form of TB in around 10% of those infected.
  • July 10, 2019
  • Human health

The reasons for this are poorly understood, but now a proof-of-concept trial using Actiphage®, a novel blood test for human TB, has revealed new insights, according to research published in medical journal Clinical Infectious Diseases.

Early detection would enable better disease management

The trial took place across Leicester’s Hospitals, a city that has one of the highest TB rates in England with between 160 and 200 new cases identified each year. Around 65% of all cases require some form of invasive investigation to obtain the diagnosis.

The experimental study, carried out at the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (BRC) and the University of Nottingham’s School of Biosciences, used Actiphage to look for the presence of the bacteria that cause TB (Mycobacterium tuberculosis; MTB).

It involved 66 participants in four groups: those with active pulmonary TB, those with latent TB, a control group of patients referred for suspected TB but found not to have the disease, and a control group of healthy individuals. The new blood test was used to test all of the patients twice, 12 months apart.

None of the participants in the control groups tested positive with Actiphage and none of the patients with latent TB who tested negative with Actiphage went on to develop active TB.

Intriguingly, two of the three participants with latent TB infection who tested positive with Actiphage went on to develop the disease more than six months later, suggesting the test may have a predictive role in identifying people with the infection at risk of developing the disease.

Potential for development as mainstream diagnostic

Senior author of the paper, Dr Pranabashis Haldar, Consultant in Respiratory Medicine at Leicester’s Hospitals and Clinical Senior Lecturer at the University of Leicester, said, “TB is the leading cause of death from an infectious disease.

“It most commonly affects the lungs and from this site is transmitted to others by coughing and sneezing. As there is a lack of diagnostic tools for people unable to bring up sputum, diagnosis is delayed, increasing the likelihood that the disease is spread.

“Our observations provide new insights into how human TB develops and support recent evidence of the existence of a transitional state of TB infection called incipient TB that does not produce symptoms but carries a high risk of progressing to active TB.

“There is potential for Actiphage to be developed, both as a mainstream blood test to diagnose TB and as a test used in screening programmes to help us identify and treat people with latent infection.

“As a blood test, it is particularly suitable for patients unable to produce sputum, including children, and may help support diagnosis in underserved groups that struggle to access freely available healthcare resources.”

Specific bacteriophage rapidly identifies infection

The cause of TB is Mycobacterium tuberculosis (MTB), a slow growing bacteria that has tough cell walls. These factors have made it difficult to detect, but Actiphage uses a specific bacteriophage that infects live MTB and breaks open the cells to release DNA, which can then be identified.

The test, developed by the University of Nottingham in conjunction with the UK’s Royal Veterinary College, has been commercialised by PBD Biotech for major diseases in livestock, primarily as a blood or milk test for bovine TB and Johne’s disease. The whole testing process can be completed in as little 6 hours.

This is the first time the blood test has been trialled in humans.

Exciting development invites further study

Co-author Dr Ben Swift, co-founder of PBD Biotech and Research Fellow at the Royal Veterinary College, said, “Actiphage is novel blood test for TB and is being used for disease management within agriculture where early detection can prevent the unnecessary destruction of the herd.

“Within the human population it offers the potential to target those at risk of the disease and save lives.”

Commenting on the study, co-author Dr Catherine Rees, Chief Scientific Officer at PBD Biotech and Associate Professor in Microbiology at the University of Nottingham, added, “The data from our initial study in humans suggest that following infection, MTB is circulating in the blood at levels that were previously undetectable, and that the immune system may be failing to effectively contain the bacteria within the lungs.

“While we are cautious about generalising from a small sample size, we are optimistic that these initial findings indicate that Actiphage can be used as a tool to help us better understand the dynamics of the infection in humans.

“The new Actiphage blood test offers the potential to target those at risk of TB and allow treatment to start early. This is a very exciting development that invites further study.”

The paper, ‘A novel high sensitivity bacteriophage-based assay identifies low level M. tuberculosis bacteraemia in immunocompetent patients with active and incipient TB’, can be accessed online at Clinical Infectious Diseases.

Read all about it

Read more on this story, as reported on in leading global news sites GenomeWeb, EurekAlert!, Medical Xpress, Medical Device Network and Select Science amongst others.

Share:

Related posts

Loading...
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

November 21, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in 8 years. A key recommendation of the report is to universally replace sputum microscopy with rapid molecular diagnostics.
Global Plan to End TB cost of inaction

Improved diagnostics priority in Global Plan to End TB

November 21, 2022
The Global Plan to End TB is a costed public health plan. It aims to cut deaths by 90% in...
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic with potential to revolutionise management of TB.
Pictured from left are Ray Harris from Foresight, Sandy Reid of Mercia Asset Management, Jane Theaker of PBD Biotech and Mark Wilcockson of British Business Bank

PBD Biotech raises further £2.4m for its breakthrough tuberculosis blood test

October 17, 2022
Human tuberculosis is second only to Covid as the world’s most fatal infectious disease. PBD Biotech has developed a diagnostic...
Rapid Research in Diagnostics Development for TB Network R2D2 TB Network

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

September 30, 2022
Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech, developers of Actiphage - a rapid blood test for early-stage tuberculosis - is partnering with the Rapid Research in Diagnostics...
Rapid Research in Diagnostics Development for TB Network R2D2 TB Network

Promising TB diagnostic Actiphage selected for evaluation by R2D2 TB Network

September 30, 2022
Ease of use at the point of need is vital for the roll out of a diagnostic, so PBD Biotech,...
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
1 2 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More